全文获取类型
收费全文 | 37602篇 |
免费 | 1606篇 |
国内免费 | 1833篇 |
学科分类
医药卫生 | 41041篇 |
出版年
2024年 | 70篇 |
2023年 | 231篇 |
2022年 | 235篇 |
2021年 | 237篇 |
2020年 | 260篇 |
2019年 | 247篇 |
2018年 | 272篇 |
2017年 | 172篇 |
2016年 | 190篇 |
2015年 | 250篇 |
2014年 | 725篇 |
2013年 | 582篇 |
2012年 | 4730篇 |
2011年 | 5214篇 |
2010年 | 1241篇 |
2009年 | 835篇 |
2008年 | 3226篇 |
2007年 | 3477篇 |
2006年 | 3197篇 |
2005年 | 2983篇 |
2004年 | 2586篇 |
2003年 | 2123篇 |
2002年 | 1788篇 |
2001年 | 1143篇 |
2000年 | 1391篇 |
1999年 | 776篇 |
1998年 | 430篇 |
1997年 | 300篇 |
1996年 | 269篇 |
1995年 | 263篇 |
1994年 | 206篇 |
1993年 | 169篇 |
1992年 | 169篇 |
1991年 | 160篇 |
1990年 | 116篇 |
1989年 | 114篇 |
1988年 | 100篇 |
1987年 | 89篇 |
1986年 | 83篇 |
1985年 | 64篇 |
1984年 | 66篇 |
1983年 | 39篇 |
1982年 | 45篇 |
1981年 | 45篇 |
1980年 | 25篇 |
1979年 | 25篇 |
1978年 | 13篇 |
1977年 | 7篇 |
1964年 | 8篇 |
1958年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Zeyu Li Erwei Hao Rui Cao Si Lin Linghui Zou Tianyan Huang Zhengcai Du Xiaotao Hou Jiagang Deng 《中草药(英文版)》2022,14(4):479-493
Zedoary tumeric (Curcumae Rhizoma, Ezhu in Chinese) has a long history of application and has great potential in the treatment of liver cancer. The anti liver cancer effect of zedoary tumeric depends on the combined action of multiple pharmacodynamic substances. In order to clarify the specific mechanism of zedoary tumeric against liver cancer, this paper first analyzes the mechanism of its single pharmacodynamic substance against liver cancer, and then verifies the joint anti liver cancer mechanism of its "pharmacodynamic group". By searching the research on the anti hepatoma effect of active components of zedoary tumeric in recent years, we found that pharmacodynamic substances, including curcumol, zedoarondiol, curcumenol, curzerenone, curdione, curcumin, germacrone, β-elemene, can act on multi-target and multi-channel to play an anti hepatoma role. For example, curcumin can regulate miR, GLO1, CD133, VEGF, YAP, LIN28B, GPR81, HCAR-1, P53 and PI3K/Akt/mTOR, HSP70/TLR4 and NF-κB. Wnt/TGF/EMT, Nrf2/Keap1, JAK/STAT and other pathways play an anti hepatoma role. Network pharmacological analysis showed that the core targets of the "pharmacodynamic group" for anti-life cancer are AKT1, EGFR, MAPK8, etc, and the core pathways are neuroactive live receiver interaction, nitrogen metabolism, HIF-1 signaling pathway, etc. At the same time, by comparing and analyzing the relationship between the specific mechanisms of pharmacodynamic substance and "pharmacodynamic group", it is found that they have great reference significance in target, pathway, biological function, determination of core pharmacodynamic components, formation of core target protein interaction, in-depth research of single pharmacodynamic substance, increasing curative effect and so on. By analyzing the internal mechanism of zedoary tumeric pharmacodynamic substance and "pharmacodynamic group" in the treatment of liver cancer, this paper intends to provide some ideas and references for the deeper pharmacological research of zedoary tumeric and the relationship between pharmacodynamic substance and "pharmacodynamic group". 相似文献
2.
目的:比较左西孟旦与米力农治疗顽固性心力衰竭(Refractory Heart Failure,RHF)的临床疗效、安全性和药物经济学价值.方法:选取2020年至2021年就诊于我院普内科的80例RHF患者,随机分成左西孟旦组和米力农组,分别于治疗前、治疗5d后采用心脏彩超测定左室射血分数(Left ventricular ejaculation fraction,LVEF)、左室舒张末腔径(Left ventricular end-diastolic diameter,LVEDD),并采用免疫荧光法检测B型脑钠肽(B-type brain natriuretic peptide,BNP)水平,计算两种治疗药物的成本-效果比.结果:与治疗前比较,治疗后左西孟旦组患者血浆BNP、LVEDD明显下降,LVEF明显升高(P<0.05);治疗后米力农组患者血浆BNP明显下降(P<0.05),LVEF明显升高(P<0.05),而LVEDD无明显变化(P>0.05);与米力农组比较,左西孟旦组疗效更高(P<0.05),不良反应发生率更低(P<0.05);米力农组成本-效果比为58.16;左西孟旦组成本-效果比为39.04小于米力农组.结论:左西孟旦和米力农均可用于RHF的治疗,但左西孟旦疗效更好,安全性和药物经济学价值更高. 相似文献
3.
4.
2019年12月我国湖北省武汉市爆发新型冠状病毒(2019-nCoV)感染疫情,目前已蔓延至全国各地,流行病学显示人群对该病毒普遍易感,且患有基础疾病的患者是重症、危重症的高危人群,同时儿童青少年感染病例数正日益增多。慢性心力衰竭儿童因其基础条件差,感染2019-nCoV后将给此类患儿的诊治带来严峻的挑战。结合儿童2019-nCoV感染的临床特点及儿童慢性心力衰竭的诊治要点,在此提出慢性心力衰竭儿童2019-nCoV感染的临床管理建议,以供临床参考。 相似文献
5.
目的:评估2型糖尿病患者正常范围尿白蛋白与肌酐比值(urine albumin-to-creatinine ratio,UACR)与高血压风险的相关性。方法:本研究纳入1 309例中国台湾李氏联合诊所定期随访的2型糖尿病患者,随访3~12年(平均6年)。根据UACR的四分位数水平将患者分为第1分位组即UACR<5.87 mg/g组(n=320)、第2分位组即5.87 mg/g≤UACR≤9.55 mg/g组(n=341)、第3分位组即9.56 mg/g≤UACR≤16.27 mg/g组(n=321)和第4分位组即16.27mg/g 相似文献
6.
7.
8.
9.
10.
Abnormal accumulation ofα-synuclein contributes to the formation of Lewy bodies in the substantia nigra,which is considered the typical pathological hallmark of Parkinson's disease.Recent research indicates that angiotensin-(1-7)plays a crucial role in several neurodegenerative disorders,including Parkinson's disease,but the underlying mechanisms remain elusive.In this study,we used intraperitoneal administration of rotenone to male Sprague-Dawley rats for 4 weeks to establish a Parkinson's disease model.We investigated whether angiotensin-(1-7)is neuroprotective in this model by continuous administration of angiotensin-(1-7)into the right substantia nigra for 4 weeks.We found that angiotensin-(1-7)infusion relieved characteristic parkinsonian behaviors and reducedα-synuclein aggregation in the substantia nigra.Primary dopaminergic neurons were extracted from newborn Sprague-Dawley rat substantia nigras and treated with rotenone,angiotensin-(1-7),and/or the Mas receptor blocker A-779 for 24 hours.After binding to the Mas receptor,angiotensin-(1-7)attenuated apoptosis andα-synuclein aggregation in rotenone-treated cells.Primary dopaminergic neurons were also treated with angiotensin-(1-7)and/or the autophagy inhibitor 3-methyladenine for 24 hours.Angiotensin-(1-7)increasedα-synuclein removal and increased the autophagy of rotenone-treated cells.We conclude that angiotensin-(1-7)reducesα-synuclein aggregation by alleviating autophagy dysfunction in Parkinson's disease.Therefore,the angiotensin-(1-7)/Mas receptor axis plays an important role in the pathogenesis of Parkinson's disease and angiotensin-(1-7)has potential therapeutic value for Parkinson's disease.All experiments were approved by the Biological Research Ethics Committee of Nanjing First Hospital(approval No.DWSY-2000932)in January 2020. 相似文献